ViaCyte

ViaCyte

ViaCyte is a biotechnology company using stem cells to create pancreatic beta cell precursors for treating diabetes.

ViaCyte is a biotechnology company using stem cells to create pancreatic beta cell precursors for treating diabetes that is headquartered in San Diego, California and was founded in 1999 by Paul Laikind.

Timeline

May 26, 2020
ViaCyte raises a $27,000,000 series D round from Bain Capital Life Sciences.
December 2018
ViaCyte raises a $80,000,000 series D round from Bain Capital Ventures and RA Capital Management.
November 2018
ViaCyte raises a $80,000,000 series D round from RA Capital Management, Texas Pacific Group, Bain Capital Life Sciences and Sanderling Ventures.
July 16, 2007
ViaCyte raises a $25,000,000 series C round from Sanderling Ventures and Pacific Horizon Ventures.
1999
ViaCyte was founded.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
ViaCyte funding round, May 2006
20,000,000
May 3, 2006
7 Results
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

$10 Million Grant to ViaCyte from Gore Supports Cell-Based Treatment for Diabetes

Beyondtype1

Web

Center for Beta Cell Therapy in Diabetes and ViaCyte Announce Start of European Clinical Trial of Human Stem Cell-derived Implants in Type 1 Diabetes Patients

ViaCyte, Inc.

Web

ViaCyte encapsulated islet cells show survival success in type 1 diabetes trial

Benedict Jephcote

Web

ViaCyte Secures $80 Million Financing to Advance Functional Cures for Insulin-Requiring Diabetes

ViaCyte, Inc.

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
ViaCyte, Inc.
January 27, 2021
www.prnewswire.com:443
/PRNewswire/ -- ViaCyte, Inc., a clinical-stage regenerative medicine company, today announced the appointment of Michael Yang to President and CEO and as a...
BioSpace
May 28, 2020
BioSpace
ViaCyte, Inc. , a privately held regenerative medicine company, announced today that ViaCyte's President and CEO Paul Laikind , Ph.D. is scheduled to present at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 at 10 a.m. Eastern Time in Track 9. The company recently announced a $27 million financing to advance
FinSMEs
May 26, 2020
FinSMEs
About | Advertise | Contact | Disclaimer | News | The Daily Deal Newsletter FinSMEs.com by FinSMEs is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.